Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon's Nuvigil Will Be Discounted To Provigil, But Not "At A Low Price"

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon will encourage patients to switch to follow-on Nuvigil by increasing the Provigil price "dramatically" ahead of generic competition. The company will file the Nuvigil NDA within the next couple of weeks.

You may also be interested in...



Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch

The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.

Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch

The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.

Cephalon’s Nuvigil Filing Remains On Schedule For First Quarter

Cephalon's modafinil follow-on Nuvigil (armodafinil) showed statistical significance in each of four pivotal studies intended to support a first-quarter NDA filing, the firm announced Feb. 10

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel